- Home
- » Tags
- » Vantictumab
Top View
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- 2018 NCI SBIR INVESTOR INITIATIVES COMPANY PROFILES Short Summary of Company
- Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: an Emerging Reality? Benjamin A
- Pancreatic Cancer
- Targeting Oncoimmune Drivers of Cancer Metastasis
- Oncomed Pharmaceuticals Inc
- Adipocytes Sustain Pancreatic Cancer Progression Through a Non-Canonical WNT Paracrine Network Inducing ROR2 Nuclear Shuttling
- Wnt/Β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
- Gm, Ke, Lr, Ls, Mw, Mz, Na, Rw, Sd, Sl, St, Sz, Tz, Ug, Zm, Zw
- Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
- Memorial Sloan Kettering ASCO Meeting Abstracts 2016
- QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- (INN) for Biological and Biotechnological Substances
- Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
- First-In-Human Evaluation of the Human Monoclonal Antibody Vantictumab (OMP-18R5; Anti- Frizzled) Targeting the WNT Pathway in A
- 32Nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two National Harbor, MD, USA
- WO 2015/036956 Al 19 March 2015 (19.03.2015) P O P C T
- WO 2017/106656 Al 22 June 2017 (22.06.2017) W P O P C T
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- (12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al